Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01520844 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

the ANRS CO21 " Extreme " Cohort (CODEX)

Study acronym: CODEX
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 300 to 450
    • Primary completion date: Sep 2022 to Sep 2029
    • Study completion date: Sep 2023 to Sep 2030
    v11
  2. Re-verified, no change to tracked fieldsv10
  3. Primary completion date: Feb 2018 to Sep 2022
    • Study completion date: Sep 2019 to Sep 2023
    v9
  4. Primary completion date: Feb 2017 to Feb 2018
    • Study completion date: Feb 2018 to Sep 2019
    v8
  5. 2 versions Re-verified since Jun 27, 2016, no change to tracked fieldsv6-v7
Show 4 earlier versionsHide 4 earlier versions
  1. Eligibility criteria expanded, about 180 words
    • Study description expanded, about 627 words
    • Study title expanded, about 2 words
    v5
  2. 2 versions Re-verified since Jul 2, 2013, no change to tracked fieldsv3-v4
  3. Lead sponsor: French National Agency for Research on AIDS and Viral Hepatitis to ANRS, Emerging Infectious Diseases
    • Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    • Study arms: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A consortium of research teams has studied the immunovirological characteristics of these patients: The ANRS CO15 ALT cohort The ANRS CO18 HIV Controller cohort the ANRS EP47 VISCONTI study
Trial Details
NCT Number NCT01520844
Lead Sponsor ANRS, Emerging Infectious Diseases
Conditions
(from sponsor)		 HIV Infection
Related terms HIV Infections
Enrollment 450 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov